The tweet was deleted by the author.
But we saved everything 🙂.
Castle Biosciences has announced new data regarding its DecisionDx-Melanoma test, which will be presented at two major upcoming industry gatherings. The company will share the findings at the Society of Dermatology Physician Associates (SDPA) 24th Annual Fall Dermatology Conference, taking place from November 11 to 15, 2026 in Hollywood, Florida, as well as at the 3rd European Congress on Dermato-Oncology (Dermato-Onco2026).
These events are significant forums for introducing clinical innovations to industry professionals in dermatology and oncology.
View post on X Loading...